HSV antivirals - current and future treatment options
HSV antivirals - current and future treatment options
复制标题
DOI：
10.1016/j.coviro.2016.01.013
复制
发表时间：
2016-06-01
影响因子：
5.9
通讯作者：
Zimmermann, Holger
中科院分区：
文献类型：
--
作者：
Birkmann, Alexander;Zimmermann, Holger
1型和2型单纯疱疹病毒（HSV）可引起感染，临床表现范围从良性和一般自限性水泡或疮，如在唇疱疹和生殖器疱疹中所见，到严重的，在罕见情况下甚至危及生命的感染。目前，已批准的单纯疱疹病毒治疗药物几乎都是核苷类似物。新的抗病毒方法包括治疗性疫苗，最先进的已成功完成2期临床开发。此外，正在开发用于治疗生殖器或唇HSV感染的几种小分子方法。特别令人感兴趣的是两种新的化合物（amenamevir和pritelivir），属于一类新的解旋酶-引发酶抑制剂，具有有希望的2期数据。
Herpes simplex virus (HSV) types 1 and 2 can cause infections with clinical manifestations ranging from benign and generally self-limiting blisters or sores as seen in labial and genital herpes through to severe and in rare cases even life-threatening infections. At present, approved treatments for herpes simplex virus are almost all nucleoside analogs. Novel antiviral approaches include therapeutic vaccines, with the most advanced having successfully completed Phase 2 clinical development. Moreover, several small molecules approaches are being developed for the treatment of genital or labial HSV infections. Of particular interest are two novel compounds (amenamevir and pritelivir) belonging to the new class of helicase-primase inhibitors with promising Phase 2 data.